Your Shopping Cart Is Empty
| Report Code: A12445 | Jul 2021 | Pages: 180 | ||
| Tables: 148 | Charts: 23 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Genome Editing Market
Request Now !The global genome editing market was valued at $4,811.04 Million in 2020 and is projected to reach $36,060.95 Million by 2030 registering a CAGR of 22.30% from 2021 to 2030.
Genome editing is also referred to as gene editing, a group of technologies that enables researchers to change the DNA of an organism. These technologies allow addition, removal or alteration of genetic material at specific locations in the genome. In addition, various approaches have been developed for genome editing. A recent one is called CRISPR-Cas9, short for regularly clustered regularly interspaced short palindrome repeats and CRISPR-associated protein9. Furthermore, a lot of excitement has been generated in the scientific community through the CRISPR-Cas9 system, which is faster, cheaper, and more efficient than other existing genome editing methods.
Moreover, the prevention and treatment of human diseases is of great importance to genome editing. Most research is currently being done on genome editing to better understand diseases using cell and animal models. Scientists are still investigating whether this approach is safe and effective for human use. It is being explored in research on a wide range of diseases, such as single-gene diseases like hemophilia, cystic fibrosis, and sickle cell disease. It also has the potential to treat and prevent complex diseases such as heart disease, cancer, human immunodeficiency virus (HIV) infection, and mental illness.
Continuous technological advancements in gene-editing tools is a major factor driving the growth of the market. Furthermore, availability of government funding & growth in number of genomics projects and rise in prevalence of cancer & other genetic disorders are projected to also drive the market growth. In addition, development of CRISPR -based novel diagnostic tools to mitigate the adverse impact of the COVID-19 pandemic also boost the genome editing market growth. Conversely, high cost of genomic equipment and increase in concerns about the risks and ethical issues associated with genome editing are some restraints that hinder the growth of the market to some extent. On the other hand, presence of key players in emerging economies and applications in several drug discovery processes are few of the factors create lucrative opportunities for the genome editing market in the near future.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. Moreover, there has also been a moderate effect on various healthcare services, including the including genome editing market. When COVID-19 was first identified, many researchers redirected their focus to the study of this novel virus and the disease it causes. Individuals working with CRISPR were no exception, and the gene editing tool was soon taken to the frontlines in the worldwide war against COVID-19. Furthermore, with the technology based upon a naturally occurring bacterial gene editing system that plays a key role the prokaryotic defense against viral infection, the CRISPR—Cas system is designed to fight viruses. The challenge researchers are facing now is how best to utilize its natural ability and optimize it for human benefit. At this time, scientists have certainly risen to the occasion and CRISPR technology has been successfully used to develop rapid diagnostic tests for COVID-19 – gaining its first US FDA (MD, USA) approval in the process. Furthermore, development of CRISPR -based novel diagnostic tools to ease the adverse impact of the COVID-19 pandemic is driving the market. For instance, in March 2021, a team of researchers from the Nanyang Technological University developed a diagnostic test - VaNGuard (Variant Nucleotide Guard) based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, thereby increasing the adoption of CRISPR genome editing technology in the diagnostics field. Hence, the overall impact of COVID-19 on genome editing market is positive, which will further drive the market growth.
The global genome editing market is segmented on the basis of application, technology, end user and region. On the basis of application, the market is further classified into cell line engineering, genetic engineering, drug discovery, gene modified cell therapy & diagnostics and other applications. By technology, it is divided into CRISPR, TALEN, ZFN and other technologies. Based on end user, it is subdivided in to academics & government institutes, biotechnology & pharma companies, contract research organizations. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Review
By technology, the CRISPR segment accounted for the largest share of the genome editing market in 2020. The large share of this segment can be attributed to the ease of use associated with CRISPR, which gives it a significant advantage over ZFN and TALEN.
Pharmaceutical companies segment accounted for the largest share of the genome editing market in 2020. The increasing prevalence of infectious diseases and cancer is driving research activities worldwide. This is expected to drive the demand for genome editing in biotechnology & pharmaceutical companies.
North America is projected to account for a major share of the global genome editing market during the forecast period. The market in the region is anticipated to grow in the future, owing to development of gene therapy in the U.S., rise in use of genetically modified crops, surge in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling market growth in North America.
The key market players profiled in the report include Agilent Technologies, CRISPR Therapeutics, Danaher, Eurofins Scientific, Editas Medicine, GenScript, Horizon Discovery Limited, Lonza, Merck and Thermo Fisher Scientific.
Key Benefits For Stakeholders
Key Market Segments
By Application
By Technology
By End User
By Region
Genome Editing Market Report Highlights
| Aspects | Details |
|---|---|
| By Application |
|
| By Technology |
|
| By End User |
|
| By Region |
|
| Key Market Players | EDITAS MEDICINE, INC, MERCK KGAA, PERKINELMER, INC., .LONZA GROUP LTD., GENSCRIPT BIOTECH CORPORATION, EUROFINS SCIENTIFIC, THERMO FISHER SCIENTIFIC, INC., CRISPR Therapeutics AG, AGLIENT TECHNOLOGIES, INC., DANAHER CORPORATION |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in adoption of genome editing applications.
3.5.1.2.Rise in prevalence of cancer & other genetic disorders
3.5.1.3.Continuous technological advancements in gene-editing tools
3.5.1.4.Availability of government funding & growth in the number of genomics projects
3.5.2.Restraint
3.5.2.1.Ethical Issues Associated with Genome Editing
3.5.3.Opportunity
3.5.3.1.Presence of key players in emerging economies and applications in several drug discovery processes
3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on the genome editing market
CHAPTER 4:GENOME EDITING MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Cell line engineering
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Genetic engineering
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Gene-modified cell therapy and Diagnostics
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Drug discovery
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Other applications
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
CHAPTER 5:GENOME EDITING MARKET, BY TECHNOLOGY
5.1.Overview
5.1.1.Market size and forecast
5.2.CRISPR
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by type
5.2.4.Academics & Government Institutes
5.2.4.1.Market size and forecast
5.2.5.Biotechnology & pharma companies
5.2.5.1.Market size and forecast
5.2.6.Contract research organizations
5.2.6.1.Market size and forecast
5.3.TALEN
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by type
5.3.4.Academics & Government Institutes
5.3.4.1.Market size and forecast
5.3.5.Biotechnology & pharma companies
5.3.5.1.Market size and forecast
5.3.6.Contract research organization
5.3.6.1.Market size and forecast
5.4.ZFN
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.4.3.Market size and forecast, by type
5.4.4.Academics & Government Institutes
5.4.4.1.Market size and forecast
5.4.5.Biotechnology & Pharma Companies
5.4.5.1.Market size and forecast
5.4.6.Contract Research Organizations
5.4.6.1.Market size and forecast
5.5.Other technologies
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
5.5.3.Market size and forecast, by type
5.5.4.Academics & Government Institutes
5.5.4.1.Market size and forecast
5.5.5.Biotechnology & Pharma Companies
5.5.5.1.Market size and forecast
5.5.6.Contract research organizations
5.5.6.1.Market size and forecast
CHAPTER 6:GENOME EDITING MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Academics & government institutes
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Biotechnology & pharma companies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Contract Research Organization
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:GENOME EDITING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S. genome editing market, by application
7.2.2.2.U.S. genome editing market, by technology
7.2.2.3.U.S. genome editing market, by end user
7.2.2.4.Canada genome editing market, by application
7.2.2.5.Canada genome editing market, by technology
7.2.2.6.Canada genome editing market, by end user
7.2.2.7.Mexico genome editing market, by application
7.2.2.8.Mexico genome editing market, by technology
7.2.2.9.Mexico genome editing market, by end user
7.2.3.North America market size and forecast, by application
7.2.4.North America market size and forecast, by technology
7.2.4.1.North America CRISPR, by end user
7.2.4.2.North America TALEN, by end user
7.2.4.3.North America ZFN, by end user
7.2.4.4.North America other technologies, by end user
7.2.5.North America market size and forecast, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany genome editing market, by application
7.3.2.2.Germany genome editing market, by technology
7.3.2.3.Germany genome editing market, by end user
7.3.2.4.France genome editing market, by application
7.3.2.5.France genome editing market, by technology
7.3.2.6.France genome editing market, by end user
7.3.2.7.UK genome editing market, by application
7.3.2.8.UK genome editing market, by technology
7.3.2.9.UK genome editing market, by end user
7.3.2.10.Italy genome editing market, by application
7.3.2.11.Italy genome editing market, by technology
7.3.2.12.Italy genome editing market, by end user
7.3.2.13.Spain genome editing market, by application
7.3.2.14.Spain genome editing market, by technology
7.3.2.15.Spain genome editing market, by end user
7.3.2.16.Rest of Europe genome editing market, by application
7.3.2.17.Rest of Europe Genome editing market, by technology
7.3.2.18.Rest of Europe Genome editing market, by end user
7.3.3.Europe market size and forecast, by application
7.3.4.Europe market size and forecast, by technology
7.3.4.1.Europe CRISPR, by end user
7.3.4.2.Europe TALEN, by end user
7.3.4.3.Europe ZFN, by end user
7.3.4.4.Europe other technologies, by end user
7.3.5.Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan Genome editing market, by application
7.4.2.2.Japan Genome editing market, by technology
7.4.2.3.Japan Genome editing market, by end user
7.4.2.4.China Genome editing market, by application
7.4.2.5.China genome editing market, by technology
7.4.2.6.China genome editing market, by end user
7.4.2.7.Australia genome editing market, by application
7.4.2.8.Australia genome editing market, by technology
7.4.2.9.Australia genome editing market, by end user
7.4.2.10.India genome editing market, by application
7.4.2.11.India genome editing market, by technology
7.4.2.12.India genome editing market, by end user
7.4.2.13.South Korea genome editing market, by application
7.4.2.14.South Korea genome editing market, by technology
7.4.2.15.South Korea genome editing market, by end user
7.4.2.16.Rest of Asia-Pacific genome editing market, by application
7.4.2.17.Rest of Asia-Pacific genome editing market, by technology
7.4.2.18.Rest of Asia-Pacific genome editing market, by end user
7.4.3.Asia-Pacific market size and forecast, by application
7.4.4.Asia-Pacific market size and forecast, by technology
7.4.4.1.Asia-Pacific CRISPR, by end user
7.4.4.2.Asia-Pacific TALEN, by end user
7.4.4.3.Asia-Pacific ZFN, by end user
7.4.4.4.Asia-Pacific other technologies, by end user
7.4.5.Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil genome editing market, by application
7.5.2.2.Brazil genome editing market, by technology
7.5.2.3.Brazil genome editing market, by end user
7.5.2.4.Saudi Arabia genome editing market, by application
7.5.2.5.Saudi Arabia genome editing market, by technology
7.5.2.6.Saudi Arabia genome editing market, by end user
7.5.2.7.South Africa genome editing market, by application
7.5.2.8.South Africa genome editing market, by technology
7.5.2.9.South Africa genome editing market, by end user
7.5.2.10.Rest of LAMEA genome editing market, by application
7.5.2.11.Rest of LAMEA genome editing market, by technology
7.5.2.12.Rest of LAMEA genome editing market, by end user
7.5.3.LAMEA market size and forecast, by application
7.5.4.LAMEA market size and forecast, by technology
7.5.4.1.LAMEA CRISPR, by end user
7.5.4.2.LAMEA TALEN, by end user
7.5.4.3.LAMEA ZFN, by end user
7.5.4.4.LAMEA other technologies, by end user
7.5.5.LAMEA market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.AGLIENT TECHNOLOGIES, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.CRISPR Therapeutics AG
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.DANAHER CORPORATION
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.EUROFINS SCIENTIFIC
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.EDITAS MEDICINE, INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.GENSCRIPT BIOTECH CORPORATION
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.PERKINELMER, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.LONZA GROUP LTD.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.MERCK KGAA
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and development
LIST OF TABLES
TABLE 01.GENOME EDITING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 02.CELL LINE ENGINEERING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.GENETIC ENGINEERING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04.GENE MODIFIED CELL THERAPY AND DIAGNOSTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.DRUG DISCOVERYMARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06.OTHER APPLICATIONS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07.GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030($MILLION)
TABLE 08.CRISPR MARKET, BY REGION, 2020-2030($MILLION)
TABLE 09.GENOME EDITING MARKET, FOR CRISPR, BY END USER, 2020–2030, ($MILLION)
TABLE 10.TALEN MARKET, BY REGION, 2020-2030($MILLION)
TABLE 11.GENOME EDITING MARKET, FOR TALEN, BY END USER, 2020–2030, ($MILLION)
TABLE 12.ZFN MARKET, BY REGION, 2020-2030($MILLION)
TABLE 13.GENOME EDITING MARKET, FOR ZFN, BY END USER, 2020–2030, ($MILLION)
TABLE 14.OTHER TECHNOLOGIES MARKET, BY REGION, 2020-2030($MILLION)
TABLE 15.GENOME EDITING MARKET, FOR OTHER TECHNOLOGIES, BY END USER, 2020–2030, ($MILLION)
TABLE 16.GENOME EDITING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 17.ACADEMICS & GOVERNMENT INSTITUTES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18.BIOTECHNOLOGY & PHARMA COMPANIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19.CONTRACT RESEARCH ORGANIZATION MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20.GENOME EDITING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 21.NORTH AMERICA GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 22.U.S. GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 23.U.S. GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 24.U.S. GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 25.CANADA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 26.CANADA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 27.CANADA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 28.MEXICO GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 29.MEXICO GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 30.MEXICO GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 31.NORTH AMERICA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 32.NORTH AMERICA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 33.NORTH AMERICA CRISPR, BY END USER, 2020-2030
TABLE 34.NORTH AMERICA TALEN, BY END USER, 2020-2030
TABLE 35.NORTH AMERICA ZFN, BY END USER, 2020-2030
TABLE 36.NORTH AMERICA OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 37.NORTH AMERICA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 38.EUROPE GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 39.GERMANY GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 40.GERMANY GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 41.GERMANY GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 42.FRANCE GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 43.FRANCE GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 44.FRANCE GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 45.UK GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 46.UK GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 47.UK GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 48.ITALY GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 49.ITALY GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 50.ITALY GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 51.SPAIN GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 52.SPAIN GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 53.SPAIN GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 54.REST OF EUROPE GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 55.REST OF EUROPE GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 56.REST OF EUROPE GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 57.EUROPE GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 58.EUROPE GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 59.EUROPE HOSPITALS, BY END USER, 2020-2030
TABLE 60.EUROPE TALEN, BY END USER, 2020-2030
TABLE 61.EUROPE ZFN, BY END USER, 2020-2030
TABLE 62.EUROPE OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 63.EUROPE GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 64.ASIA-PACIFIC GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 65.JAPAN GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 66.JAPAN GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 67.JAPAN GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 68.CHINA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 69.CHINA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 70.CHINA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 71.AUSTRALIA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 72.AUSTRALIA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 73.AUSTRALIA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 74.INDIA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 75.INDIA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 76.INDIA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 77.SOUTH KOREA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 78.SOUTH KOREA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 79.SOUTH KOREAGENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 80.REST OF ASIA-PACIFIC GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 81.REST OF ASIA-PACIFIC GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 82.REST OF ASIA-PACIFIC GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 83.ASIA-PACIFIC GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 84.ASIA-PACIFIC GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 85.ASIA-PACIFIC HOSPITALS, BY END USER, 2020-2030
TABLE 86.EUROPE TALEN, BY END USER, 2020-2030
TABLE 87.ASIA-PACIFIC ZFN, BY END USER, 2020-2030
TABLE 88.ASIA-PACIFIC OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 89.ASIA-PACIFIC GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 90.LAMEA GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 91.BRAZIL GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 92.BRAZIL GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 93.BRAZIL GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 94.SAUDI ARABIA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 95.SAUDI ARABIA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 96.SAUDI ARABIA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 97.SOUTH AFRICA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 98.SOUTH AFRICA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 99.SOUTH AFRICA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 100.REST OF LAMEA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 101.REST OF LAMEA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 102.REST OF LAMEA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 103.LAMEA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 104.LAMEA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 105.LAMEA CRISPR, BY END USER, 2020-2030
TABLE 106.LAMEA TALEN, BY END USER, 2020-2030
TABLE 107.LAMEA ZFN, BY END USER, 2020-2030
TABLE 108.LAMEA OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 109.LAMEA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 110.AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 111.AGILENT TECHNOLOGIES: OPERATING SEGMENTS
TABLE 112.AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 113.AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.CRISPR THERAPEUTICS: COMPANY SNAPSHOT
TABLE 115.CRISPR THERAPEUTICS: OPERATING SEGMENTS
TABLE 116.CRISPR THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 117.CRISPR THERAPEUTICS: KEY DEVELOPMENTS
TABLE 118.DANAHER: COMPANY SNAPSHOT
TABLE 119.DANAHER: PRODUCT SEGMENTS
TABLE 120.DANAHER: PRODUCT PORTFOLIO
TABLE 121.DANAHER: KEY DEVELOPMENTS
TABLE 122.EUROFINS: COMPANY SNAPSHOT
TABLE 123.EUROFINS: PRODUCT PORTFOLIO
TABLE 124.EUROFINS: KEY DEVELOPMENTS
TABLE 125.EDITAS MEDICINE: COMPANY SNAPSHOT
TABLE 126.EDITAS MEDICINE: OPERATING BUSINESS SEGMENTS
TABLE 127.EDITAS MEDICINE: PRODUCT PORTFOLIO
TABLE 128.EDITAS MEDICINE: KEY DEVELOPMENTS
TABLE 129.GENSCRIPT: COMPANY SNAPSHOT
TABLE 130.GENSCRIPT: OPERATING SEGMENTS
TABLE 131.GENSCRIPT: PRODUCT PORTFOLIO
TABLE 132.GENSCRIPT: KEY DEVELOPMENTS
TABLE 133.PERKINELMER: COMPANY SNAPSHOT
TABLE 134.PERKINELMER: OPERATING SEGMENTS
TABLE 135.PERKINELMER: PRODUCT PORTFOLIO
TABLE 136.PERKINELMER : KEY DEVELOPMENTS
TABLE 137.LONZA: COMPANY SNAPSHOT
TABLE 138.LONZA: OPERATING SEGMENTS
TABLE 139.LONZA: PRODUCT PORTFOLIO
TABLE 140.LONZA: KEY DEVELOPMENTS
TABLE 141.MERCK: COMPANY SNAPSHOT
TABLE 142.MERCK: OPERATING SEGMENTS
TABLE 143.MERCK: PRODUCT PORTFOLIO
TABLE 144.MERCK: KEY DEVELOPMENTS
TABLE 145.THERMO FISHER: COMPANY SNAPSHOT
TABLE 146.THERMO FISHER: OPERATING SEGMENTS
TABLE 147.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 148.THERMO FISHER: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.GENOME EDITING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF GENETIC ENGINEERINGMARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF GENETIC ENGINEERING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF GENE MODIFIED CELL THERAPY AND DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DRUG DISCOVERY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF OTHER APPLICATIONS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF CRISPR MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020–2030, ($MILLION)
FIGURE 20.BIOTECHNOLOGY & PHARMA COMPANIES MARKET, 2020–2030, ($MILLION)
FIGURE 21.CONTRACT RESEARCH ORGANIZATIONS MARKET, 2020–2030, ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF TALEN MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020–2030, ($MILLION)
FIGURE 24.BIOTECHNOLOGY & PHARMA COMPANIES MARKET, 2020–2030, ($MILLION)
FIGURE 25.CONTRACT RESEARCH ORGANIZATION MARKET, 2020–2030, ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF ZFN MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27.ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020–2030, ($MILLION)
FIGURE 28.BIOTECHNOLOGY & PHARMA COMPANIES MARKET, 2020–2030, ($MILLION)
FIGURE 29.CONTRACT RESEARCH ORGANIZATIONS MARKET, 2020–2030, ($MILLION)
FIGURE 30.COMPARATIVE ANALYSIS OF OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 31.ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020–2030, ($MILLION)
FIGURE 32.PHARMACEUTICAL COMPANIES MARKET, 2020–2030, ($MILLION)
FIGURE 33.CONTRACT RESEARCH ORGANIZATIONS MARKET, 2020–2030, ($MILLION)
FIGURE 34.COMPARATIVE ANALYSIS OF ACADEMICS & GOVERNMENT INSTITUTES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 35.COMPARATIVE ANALYSIS OF BIOTECHNOLOGY & PHARMA COMPANIES GENOME EDITING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 36.COMPARATIVE ANALYSIS OF CONTRACT RESEARCH ORGANIZATION MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 01.AGILENT TECHNOLOGIES: NET SALES, 2018-2020 ($MILLION)
FIGURE 02.AGILENT TECHNOLOGIES: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 03.AGILENT TECHNOLOGIES: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 04.CRISPR THERAPEUTICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 05.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 06.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 07.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 08.EUROFINS: NET SALES, 2018–2020 ($MILLION)
FIGURE 09.EUROFINS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 10.GENSCRIPT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11.GENSCRIPT: REVENUE SHARE BY REGION, 2020(%)
FIGURE 12.PERKINELMER: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.PERKINELMER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 14.PERKINELMER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 15.LONZA: NET SALES, 2018–2020 ($MILLION)
FIGURE 16.LONZA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 17.LONZA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 18.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21.THERMO FISHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)
Genome editing market growth includes increase in implementation of CRISPR genome editing technology coupled with rising synthetic gene demand in diverse biotechnology domains has primarily driven the market growth over the past few years. Moreover, continuous technological advancements in gene-editing tools are a major contributing factor for revenue generation in this market. Moreover, the market is witnessing intensified competition among the market players owing to the expanding applications of genome editing tools. There has been an increased focus on the highly adaptable CRISPR technology. Genome editing has indicated a good potential for the treatment of genetic disorders, infectious diseases, and cancer. Along with the advantages, there are growing concerns about the risks and ethical issues associated with genome editing that affect the market. The major ethical issues, include the off-target mutation development, imbalance of the environment, and illegal usage of genome editing.
Furthermore, genome editing market is dominated by North America due to the strong growth trend in the pharmaceuticals and biotechnology industries and is followed by Europe. The large share of North America can be attributed to factors such as the development of gene therapy in the U.S., the rising prevalence of infectious diseases and cancer, and the availability of research grants and funding, which are propelling the market growth in North America.
A. The total market value of Genome Editing market is $4,811.04 million in 2020.
A. The forcast period for Genome Editing market is 2021 to 2030
A. The market value of Genome Editing market in 2021 is $5,893.53 million.
A. The base year is 2020 in Genome Editing market
A. Top companies such as Agilent Technologies, CRISPR Therapeutics, Danaher, Eurofins Scientific, Editas Medicine ,GenScript, Horizon Discovery Limited, Lonza, Merck and Thermo Fisher Scientific held a high market position in 2020.
A. Based on technology, the CRISPR segment accounted for the largest share of the genome editing market in 2020. The large share of this segment can be attributed to the ease of use associated with CRISPR, which gives it a significant advantage over ZFN and TALEN
A. Continuous technological advancements in gene-editing tools is a major factor driving the growth of the market. Furthermore, availability of government funding, growth in the number of genomics projects and rise in prevalence of cancer & other genetic disorders will also drive the market growth. In addition, development of CRISPR-based novel diagnostic tools to mitigate adverse impact of the COVID-19 pandemic also boost the genome editing market growth
A. North America is projected to account for a major share of the global genome editing market during the forecast period. The market in the region is anticipated to grow in the future, owing to development of gene therapy in the U.S., increase in use of genetically modified crops, rise in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling the market growth in North America.
A. Genome Editing products that are dry and used as primary or secondary dressings to protect the wound from infection
A. Gene editing has indicated a good potential for the treatment of genetic disorders, infectious diseases, and cancer.
Start reading instantly.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report